Yi Zhang

Yi Zhang

Auto-generated profile, based on publicly available information

Yi Zhang

Medical Technology and Practice Patterns Institute, Bethesda, Maryland, USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
MTMae Thamer
Mae Thamer
JKJames S. Kaufman
James S. Kaufman
YZYi Zhang
Yi Zhang
QZQian Zhang
Qian Zhang
DCDennis J. Cotter
Dennis J. Cotter
HBHeejung Bang
Heejung Bang

1 November 2004
Verified
Journal Article
Closed access
YZYi Zhang
Yi Zhang
MTMae Thamer
Mae Thamer
KSKevin Stefanik
Kevin Stefanik
JKJames Kaufman
James Kaufman
DCDennis J Cotter
Dennis J Cotter

9 December 2010 in Health Services Research
Verified
Journal Article
Closed access
PDF file
YZYi Zhang
Yi Zhang
DCDennis J. Cotter
Dennis J. Cotter
MTMae Thamer
Mae Thamer

30 May 2017 in Health Services Research
Verified
Journal Article
Closed access
PDF file
YZYi Zhang
Yi Zhang
JYJessica G. Young
Jessica G. Young
MTMae Thamer
Mae Thamer
MHMiguel A. Hernán
Miguel A. Hernán

1 March 2014 in Medical Care
Verified
Journal Article
Closed access
YZYi Zhang
Yi Zhang
MTMae Thamer
Mae Thamer
JKJames Kaufman
James Kaufman
DCDennis Cotter
Dennis Cotter
MHMiguel A. Hernán
Miguel A. Hernán
Background: Randomized trials found that use of erythropoiesis-stimulating agents to target normal hematocrit (Hct) levels (>39%) compared with 27%–34.5% increases cardiovascular risk and mortality among chronic kidney disease patients. However, the effects of the most widely used Hct target in the past 2 decades, 34.5%–39%, have never been examined. Objective: To compare the effects of 2 Hct target strategies—30.0%–34.5% (low) and 34.5%–39.0% (mid) in a high-risk population: elderly dialysis patients with significant comorbidities. Research Design: Observational data from the US Renal Data System were used to emulate a randomized trial in which patients were assigned to either Hct strategy. Follow-up started after completing 3 months of hemodialysis and ended 6 months later. We conducted the observational analogs of intention-to-treat and per-protocol analyses. Inverse-probability weighting was used to adjust for measured time-dependent confounding by indication. Subjects: A total of 22,474 elderly patients with both diabetes and cardiovascular disease who initiated hemodialysis in 2006–2008. Measures: Hazard ratios (HRs) and survival probabilities for all-cause mortality and a composite cardiovascular and mortality endpoint. Results: The intention-to-treat HR (95% confidence interval) for mid versus low Hct strategy was 1.05 (0.99–1.11) for all-cause mortality and 1.03 (0.98–1.08) for the composite endpoint. The per-protocol HR (95% confidence interval) for mid versus low Hct strategy was 0.98 (0.78–1.24) for all-cause mortality and 1.00 (0.81–1.24) for the composite outcome. Conclusions: Among hemodialysis patients, we did not find differences in 6-month survival or cardiovascular risk between clinical strategies that target Hct at 30.0%–34.5% versus 34.5%–39.0%.

1 May 2017 in Kidney International Reports
Verified
Journal Article
Open access
QZQian Zhang
Qian Zhang
MTMae Thamer
Mae Thamer
OKOnkar Kshirsagar
Onkar Kshirsagar
YZYi Zhang
Yi Zhang
The End Stage Renal Disease (ESRD) Prospective Payment System (PPS), implemented by the Centers for Medicare and Medicaid Services in January 2011, encouraged use of peritoneal dialysis (PD) through various financial incentives. Our goal was to determine whether PPS effectively increased PD use in incident dialysis patients. Our study used the United States Renal Data System (USRDS) to identify 430,927 adult patients who initiated dialysis between 2009 and 2012. The interrupted time series method was used to evaluate the association Centers for Medicare and Medicaid Services of PPS with PD use at dialysis initiation. We further stratified by patient demographics, predialysis care, and facility chain and profit status. Interrupted time series analysis indicated PPS was associated with increased PD use in the 2-year period after PPS (change in slope = 0.04, P < 0.0001), although there was no immediate change in the level of PD use at the beginning of PPS (P = 0.512). Stratified analyses indicated PPS led to increased PD use across all age, race, and sex groups (P < 0.05) although marginally among females (P = 0.09). Notably, small dialysis organizations and nonprofit organizations appeared to increase use of PD faster compared to large dialysis organizations and for-profit units, respectively. Implementation of the Centers for Medicare and Medicaid Services ESRD payment reform was associated with an increased use of PD in the 2 years after PPS. Our findings highlight the role of financial incentives in changing practice patterns to increase use of a dialysis modality considered to be both more cost-effective and empowering to ESRD patients. However, even after PPS, rates of PD use remain low among the dialysis population in the USA.